01—Abstract
Summary
Summary of the 8-K filed June 23, 2026. Cited figures are marked; the original filing is the authoritative source.
Illumina, Inc. (NASDAQ: ILMN) filed this Current Report on Form 8-K on June 23, 2026 to report the appointment of a new director.
On June 16, 2026, the Board of Directors increased its size from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., effective immediately. Dr. Skovronsky will stand for election at the Company's 2027 annual meeting of stockholders for a one-year term commencing with that meeting.
The Board determined he is independent under Nasdaq and SEC rules, and the filing states there is no arrangement or understanding under which he was selected and no reportable related-person transaction under Item 404(a) of Regulation S-K. He will participate in the non-employee director compensation program described in the proxy statement filed on April 9, 2026. The filing attaches a press release dated June 23, 2026, which states that Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories.
The release says he previously served on the Board of Directors of Myriad Genetics, Inc. and that his experience in drug discovery, clinical development and translational medicine is relevant to Illumina's genomics and multiomics work. Chief Executive Officer Jacob Thaysen is quoted welcoming him to the Board.
The filing contains no financial results, financial statements, or quantitative disclosures. Its significance is governance-related, expanding the Board's size and adding a director with pharmaceutical R&D leadership experience.
02—Key points
Key Highlights
- Board increased from nine to ten members on June 16, 2026, with Daniel M. Skovronsky, M.D., Ph.D., appointed effective immediately.
- Dr. Skovronsky is identified as independent under Nasdaq and SEC rules.
- He will stand for election at the 2027 annual meeting of stockholders for a one-year term.
- Dr. Skovronsky is Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories.
- The filing states there is no arrangement or understanding for his selection and no reportable Item 404(a) transactions.
- He will participate in the non-employee director compensation program described in the April 9, 2026 proxy statement.
- The filing reports no financial results; its substance is governance and board composition.
03—Questions
Frequently Asked Questions
Who was appointed to Illumina's Board of Directors?
Daniel M. Skovronsky, M.D., Ph.D., was appointed effective June 16, 2026. He currently serves as Chief Scientific and Product Officer of Eli Lilly and Company.
Why did the Board expand from nine to ten members?
The filing states that the Board increased its size from nine to ten members in connection with the appointment of Dr. Skovronsky. It does not give further reasons.
Is the new director independent?
Yes. The filing states that Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission.
How will the new director be compensated and when will he face election?
He will participate in the non-employee director compensation programs described in the proxy statement filed April 9, 2026. He will stand for election at the 2027 annual meeting of stockholders for a one-year term.
Does the appointment involve any related-party transactions or special arrangements?
The filing states there is no arrangement or understanding between Dr. Skovronsky and any other person under which he was selected, and that he is not a party to any transaction reportable under Item 404(a) of Regulation S-K.
04—Continue